Newsletter | September 17, 2021

09.17.21 -- Adapting New Processes For Cell & Gene Therapies

The Raw Material Hurdle: Plasmids For Viral Vector-Based Gene Therapies

The success of using viral vectors to deliver a molecular payload into a cell or replace defective genes with functional ones is an inflection point in the future of modern medicine.

Overcoming Commercialization Challenges For Cell And Gene Therapies

This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps and strategies and solutions to facilitate development through commercialization.

Technology Integrators In Cell And Gene Therapy: Powering Innovation

Accelerated clinical trial timelines for advanced therapeutics are on the rise. With Fast Track status designations, it is increasingly critical for innovators to have efficient and scalable production processes.

Manufacturing Strategies To Effectively Industrialize Autologous Cell Therapies

While the first autologous cell therapy commercial products have shown tremendous clinical success, scaling out these therapies while considering individual patient processes is a new challenge.